EFFECT OF LIDOFLAZINE ON CORONARY FLOW RESERVE

我们之前已经证明，可能会有 综合征X(冠状动脉造影术正常但胸痛 动脉)由于冠状动脉血流受限而出现心肌缺血 储备(微血管心绞痛)。因为利多氟嗪，一种钙 进入阻滞剂，改善胸痛症状和耐力 在微血管心绞痛患者中，我们研究了 该药对10例冠心病患者冠脉血流动力学的影响 微血管心绞痛。所有人都有明显的症状 传统的钙通道阻滞剂，并已有所改善 利多拉嗪240-360 mg/d。与 冠状动脉(心脏大静脉)流量的测量 药物治疗，利多拉嗪导致冠脉流量改善 对起搏压力的反应，即使在给药麦角新碱之后也是如此 0.15 mg。此外，药物作用后的冠脉血流储备 双嘧达莫0.75 mg/kg对血管的扩张作用也显著 改进了。因此，利多拉嗪显著改善了患者的 应激和药理学冠脉血流储备，并提示 微血管心绞痛患者的冠脉血流储备 受限于与异常钙相关的血管收缩影响 助熔剂。

We have previously demonstrated that may patients with Syndrome X (chest pain despite angiographically normal coronary arteries) have myocardial ischemia due to limited coronary flow reserve (microvascular angina). Because lidoflazine, a calcium entry blocker, improves chest pain symptoms and effort tolerance in patients with microvascular angina, we studied the effect of this drug on coronary hemodyanmics in 10 patients with microvascular angina. All had been significantly symptomatic on conventional calcium channel blockers and had improved symptomatically on lidoflazine 240-360 mg/d. Compared to measurement of coronary (great cardiac vein) flow off all medications, lidoflazine resulted in improved coronary flow response to pacing stress, even after administration of ergonovine 0.15mg. Further, coronary flow reserve following pharmacologic vasodilation by dipyridamole 0.75 mg/kg was also significantly improved. Thus, lidoflazine results in significant improvement in stress and pharmacologic coronary flow reserve, and suggests that coronary flow reserve in patients with microvascular angina is limited by vasoconstrictor influences related to abnormal calcium fluxes.